• 1
    Farthing MJ. Irritable bowel syndrome: new pharmaceutical approaches to treatment. Baillieres Clin Gastroenterol 1999; 13: 46171.
  • 2
    Lee OY, Schmulson M, Mayer EA. Common functional gastrointestinal disorders: nonulcer dyspepsia and irritable bowel syndrome. Clin Cornerstone 1999; 1: 5771.
  • 3
    Wald A. Irritable bowel syndrome. Curr Treat Options Gastroenterol 1999; 2: 139.
  • 4
    Serra J, Azpiroz F, Malagelada JR. Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome. Gut 2001; 48: 149.
  • 5
    Camilleri M. Tegaserod. Aliment Pharmacol Ther 2001; 15: 27789.
  • 6
    Scott LJ, Perry CM. Tegaserod. Drugs 1999; 58: 4916.
  • 7
    Scarpignato C, Pelosini I. Management of irritable bowel syndrome: novel approaches to the pharmacology of gut motility. Can J Gastroenterol 1999; 13(Suppl. A): 50A65A.
  • 8
    Muller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001; 15: 165566.
  • 9
    Prather CM, Camilleri M, Zinsmeister AR, et al. Tegaserod accelerates orocecal transit in patients with constipation–predominant irritable bowel syndrome. Gastroenterology 2000; 118: 4638.
  • 10
    Northcutt AR, Mangel AW, Hamm LR, et al. Persistent placebo response during a year-long controlled trial of IBS treatment. Gastroenterology 2001; 120(Suppl. 1): 3243(Abstract).
  • 11
    Drossman DA, Thompson W, Talley NJ, et al. Identification of sub-groups of functional gastrointestinal disorders. Gastroenterol Int 1990; 3: 15972.
  • 12
    Drossman DA, Richter J, Talley NJ, et al. The Functional Gastrointestinal Disorders, 1st edn. McLean, VA: Degnon Associates, 1994.
  • 13
    Patrick DL, Drossman DA, Frederick IO, et al. Quality of life inpersons with irritable bowel syndrome: development andvalidation of a new measure. Dig Dis Sci 1998; 43: 40011.
  • 14
    Ruigomez A, Wallander MA, Johansson S, Garcia Rodriguez LA. One-year follow-up of newly diagnosed irritable bowel syndrome patients. Aliment Pharmacol Ther 1999; 13: 1097102.
  • 15
    Dobrilla G, Imbimbo BP, Piazzi L, Bensi G. Long-term treatment of irritable bowel syndrome with cimetropium bromide: a double blind placebo controlled clinical trial. Gut 1990; 31: 3558.
  • 16
    Gilbody JS, Fletcher CP, Hughes IW, Kidman SP. Comparison of two different formulations of mebeverine hydrochloride inirritable bowel syndrome. Int J Clin Pract 2000; 54: 4614.
  • 17
    Jones RH, Holtmann G, Rodrigo L, et al. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Aliment Pharmacol Ther 1999; 13: 141927.
  • 18
    Noor N, Small PK, Loudon MA, et al. Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome. Scand J Gastroenterol 1998; 33: 60511.
  • 19
    Centonze V, Imbimbo BP, Campanozzi F, et al. Oral cimetropium bromide, a new antimuscarinic drug, for long-term treatment of irritable bowel syndrome. Am J Gastroenterol 1988; 83: 12626.
  • 20
    Mathias JR, Clench MH, Roberts PH, Reeves-Darby VG. Effect of leuprolide acetate in patients with functional bowel disease. Long-term follow-up after double-blind, placebo-controlled study. Dig Dis Sci 1994; 39: 116370.
  • 21
    Benatar A, Feenstra A, Decraene T, Vandenplas Y. Effects of cisapride on corrected QT interval, heart rate, and rhythm in infants undergoing polysomnography. Pediatrics 2000; 106: E85.
  • 22
    Drici MD, Ebert SN, Wang WX, et al. Comparison of tegaserod (HTF 919) and its main human metabolite with cisapride and erythromycin on cardiac repolarization in the isolated rabbit heart. J Cardiovasc Pharmacol 1999; 34: 828.
  • 23
    Drolet B, Khalifa M, Daleau P, et al. Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval. Circulation 1998; 97: 20410.